TABLE 1.
Globally approved Jakinibs for varied therapeutic indications.
| S. No. | Jakinib | Targets | Current Indications | Year | Clinical trial identifier a b |
|---|---|---|---|---|---|
| 1 | Ruxolitinib | JAK1, JAK2, JAK2V617F | MF | 2011 (FDA) | NCT00952289 |
| 2012 (EMA) | NCT00934544 | ||||
| PCV | 2014 (FDA), 2015 (EMA) | NCT01243944 NCT02038036 | |||
| a/cGVHD | 2019, 2021 (FDA) | NCT02913261 | |||
| 2022 (EMA) | NCT03112603 | ||||
| Jakafi®; Incyte, Jakavi®; Novartis, Opzelura®; Incyte | NCT03147742 | ||||
| AD | 2021 (FDA) | NCT03745638 | |||
| NCT03745651 | |||||
| NsV | 2022 (FDA) | NCT04052425 | |||
| NCT04057573 | |||||
| 2 | Tofacitinib | JAK1, JAK2, JAK3 | RA | 2012 (FDA) | NCT00856544 |
| Xeljanz®; Pfizer | 2013 (MHLW, Swissmedic) | NCT00847613 | |||
| 2017 (CFDA) | NCT00814307 | ||||
| 2017 (EMA) | NCT01039688 | ||||
| PsA | 2017 (FDA) | NCT01877668 | |||
| NCT01882439 | |||||
| 2018 (EMA) | NCT01976364 | ||||
| UC | 2018 (FDA, EMA) | NCT01465763 | |||
| NCT01458951 | |||||
| NCT01458574 | |||||
| JIA | 2020 (FDA) | NCT02592434 | |||
| 2021 (EMA) | |||||
| AS | 2021 (FDA, EMA) | NCT03502616 | |||
| 3 | Oclacitinib | JAK1 | Canine AD | 2013 (FDA) | NA |
| Apoquel®; Zoetis | |||||
| 4 | Baricitinib | JAK1, JAK2 | RA | 2017 (EMA, MHLW) | NCT01721044 |
| 2018 (FDA) | NCT02265705 | ||||
| 2019 (TGA) | NCT01710358 | ||||
| AD | 2020 (EMA) | NCT03334396 | |||
| NCT03334422 | |||||
| Olumiant®; Eli lily and Incyte | COVID19 | 2022 (FDA) | NCT04401579 | ||
| NCT04421027 | |||||
| AA | 2022 (FDA, EMA) | NCT03570749 | |||
| NCT03899259 | |||||
| 5 | Peficitinib | JAK1, JAK2, JAK3, TYK2 | RA | 2019 (MHLW) | NCT02308163 |
| Smyraf®; Astellas Pharma | NCT02305849 | ||||
| 6 | Fedratinib | JAK2, JAK2V617F, FLT3 | MF | 2019 (FDA) | NCT01437787 |
| Inrebic®; Bristol Myers Squibb | 2021 (EMA) | NCT015233171 | |||
| 7 | Upadacitinib | JAK1 | RA | 2019 (FDA) | NCT02706873 |
| NCT02706951 | |||||
| NCT02629159 | |||||
| NCT02675426 | |||||
| 2021 (EMA) | NCT02706847 | ||||
| PsA | 2021 (EMA, FDA) | NCT03104400 | |||
| NCT03104374 | |||||
| AD | 2021 (EMA) | NCT03569293 | |||
| 2022 (FDA) | NCT03607422 | ||||
| NCT03568318 | |||||
| Rinvoq®; AbbVie | UC | 2022 (FDA, EMA) | NCT03006068 | ||
| NCT03653026 | |||||
| NCT02819635 | |||||
| AS | 2021 (EMA) | NCT03178487 | |||
| 2022 (FDA) | NCT04169373 | ||||
| nr-axSpA | 2022 (EMA, FDA) | NCT04169373 | |||
| 8 | Delgocitinib | JAK1, JAK2, JAK3, TYK2 | AD | 2020 (MHLW) | NCT03826901 |
| Corectim®; Japan Tobacco | NCT03725722 | ||||
| 9 | Filgotinib | JAK1 | RA | 2020 (EMA, MHLW) | NCT02889796 |
| NCT01888874 | |||||
| Jyseleca®; Galapagos NV and Gilead Sciences | UC | 2021 (EMA) | NCT02914522 | ||
| 10 | Abrocitinib | JAK1, JAK2 | AD | 2021 (EMA) | NCT03349060 |
| NCT03575871 | |||||
| NCT03720470 | |||||
| Cibinqo®; Pfizer | 2022 (FDA) | NCT03627767 | |||
| NCT03796676 | |||||
| NCT04345367 | |||||
| 11 | Pacritinib | JAK2, JAK2V617F, FLT3 | MF | 2022 (FDA) | NCT02055781 |
| Vonjo®; CTI BioPharma Corp. | |||||
| 12 | Deucravacitinib | TYK2 | PPs | 2022 (FDA) | NCT03624127 |
| Sotyktu™; Bristol Myers Squibb | NCT03611751 |
Information as of December 2022.
Information assessed from ClinicalTrials.gov, CFDA, China food and drug administration; Swissmedic, the Swiss agency for therapeutic products; TGA, therapeutic goods administration, Australia; MHLW, ministry of health, labor and welfare, Japan; MF, myelofibrosis; PCV, polycythemia vera; a/cGVHD, acute/chronic graft-versus-host-disease; AD, atopic dermatitis; NsV, nonsegmental vitiligo; RA, rheumatoid arthritis; PsA, psoriatic arthritis; UC, ulcerative colitis; JIA, Juvenile idiopathic arthritis; AS, ankylosing spondylitis; COVID-19, coronavirus disease-2019; AA, alopecia areata; nr-axSpA, non-radiographic axial spondyloarthritis; PPs, plaque psoriasis; NA, not applicable.